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Cancer, when detected at an early stage, has a very good probability of being eradicated by
surgery or radiotherapy. However, less aggressive treatments also tend to provide high rates
of cure without the side effects of radical therapy. We report on the results of our clinical
experience with photodynamic therapy (PDT) for the treatment of early carcinomas in the
upper aerodigestive tract, the esophagus, and the tracheobronchial tree. Sixty-four patients
with 101 squamous cell carcinomas were treated with three different photosensitizers:
hematoporphyrin derivative (HPD), Photofrin II, and tetra(m-hydroxyphenyl)chlorin
(mTHPC). Seventy-seven (76%) tumors showed a complete rsponse with no recurrence
after a mean follow-up period of 27 months. There was no significant difference in terms of
cure rates among the three dyes. However,mTHPC has a stronger phototoxicity and induces
a shorter skin photosensitization than either of the other photosensitizers. There were eight
major complications: three esophagotracheal fistulae after illumination with red light in the
esophagus, two esophageal stenoses following 360 circumferential irradiation, and three
bronchial stenoses. Illumination with the less penetrating green light and the use of a 180 or
240 windowed cylindrical light distributor render the risk of complications in the esophagus
essentially impossible, without reducing the efficacy ofthe treatment. Therefore,PDTmay be
considered as a safe and effective treatment for early carcinomas of the upper aerodigestive
tract, the esophagus, and the tracheobronchial tree.
Keywords: Bronchi, Esophagus, Hematoporphyrin derivative, Tetra(m-hydroxyphenyl)chlorin,
Photodynamic theraphy, Photofrin II
INTRODUCTION
Patients with head and neck cancer are at high risk
of developing additional synchronous and meta-
chronous primary tumors, not only in the upper
aerodigestive tract, but also in the esophagus and
the tracheobronchial tree [1-5]. This phenomenon
is attributed to the "field cancerization" concept,
which suggests that the long-term carcinogen expo-
sure leads to multiple genetic mutations throughout
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the aerodigestive tract epithelium [6,7]. Although
still a debatable issue, thorough pretherapy
screening and systematic follow-up ofthese patients
allow the detection of a great number of second
primary tumors at an early stage, i.e. in situ or micro-
invasive [4]. Treating these early tumors with a
nonmutilating and minimally invasive therapeutic
modality should be highly beneficial in patients with
head and neck cancer who are often in poor general
condition due to a previous radical procedure
directed towards the primary tumour or to con-
comitant diseases of the heart, lung or liver.
Photodynamic therapy (PDT), which is based
on the combined effects of a photosensitizing drug
and visible light, has the potential to cure such
early cancers [8-15]. This relatively new therapeutic
modality has the distinct advantage that it can be
repeated multiple times without inducing any
resistance or cumulative toxicity [16]. Photody-
namic therapy can also be utilized in association
with other procedures, and it does not preclude the
use ofeventual more aggressive future treatments in
case of failure.
Since 1984, we have investigated PDT for the
treatment of early squamous cell carcinoma arising
in the upper aerodigestive tract, the esophagus, and
the tracheobronchial tree. Three different photo-
sensitizers were used: hematoporphyrin derivative
(HPD), Photofrin II, and tetra(m-hydroxyphenyl)-
chlorin (mTHPC). The mTHPC, a second genera-
tion photosensitizer, was introduced in our study in
1992, because in preclinical studies it appeared to be
superior to HPD and Photofrin II in terms of
chemical purity, phototoxicity, and duration ofskin
photosensitization [17,18]. This paper reports on
our overallPDT clinical results for early cancers and
summarizes our personal view ofthe indications and
limitations of this treatment.
MATERIALS AND METHODS
Patients
From October 1984 to October 1998, 74 patients
with biopsy-proven early squamous cell carcinomas
(SCC) of the upper aerodigestive tract (UAT), the
esophagus, and the bronchi were treated by PDT
alone. Ten patients were excluded from the study
because the response to treatment could not be
evaluated. The main reasons were patient refusal,
esophagectomy for other invasive tumors and, in
one case, sudden cardiac death 2.5 months after
PDT. Among the 64 remaining patients (59 males
and 5 females; mean age 58 years; age range of43-75
years), 39 ofthem had a single early cancer, whereas
25 had two or more malignancies. The decision to
performPDT was taken by a multidisciplinary team
of head and neck surgeons, chemotherapists, and
radiotherapists. Photodynamic therapy was mainly
chosen as an alternative to more aggressive treat-
ments such as esophagectomy or pulmonary resec-
tion. However, in a few cases, patients refused
surgical treatment or were clearly not surgical
candidates due to severe cardiopulmonary disease.
All patients were volunteers and gave written
informed consent prior to therapy. Patients with
liver dysfunction, as evaluated by liver function tests
prior to therapy, were excluded from the study. For
each drug, the protocols were approved by the
Ethics Committee of the CHUV Hospital in
Lausanne.
Tumors
One hundred and one early squamous cell carci-
nomas of the oral cavity, pharynx, esophagus, and
tracheobronchial tree were treated once or more
by PDT. These tumors were detected as second
primary malignancies in patients with a primary
head and neck cancer. We considered as early
carcinomas those that were either in situ (Tis), i.e.,
intraepithelial with no invasion of the basement
membrane, or micro-invasive, i.e., with a depth of
infiltration less than 2mm in the oral cavity and the
pharynx, with no invasion beyond the muscularis
mucosae (Tla) in the esophagus, and no invasion
beyond the cartilage and the tunica muscularis in
the bronchi. Early tumors can therefore be consid-
ered as local lesions with almost no risk of develop-
ing lymp node metastasis and a high probability ofPDT FOR EARLY CANCERS 147
being completely cured [19,20]. Diagnosis and
staging of the tumors were based in all cases on
endoscopic morphological criteria as described by
Monnier et al. [21], as well as on histological
examination of biopsy specimens. Since 1993, most
of the patients with esophageal cancer underwent
endoscopic ultrasonography with 7.5 and 12MHz
probes and more recently with a high resolution
20MHz miniprobe. Esophageal carcinomas with
complete radial extension were not included in the
study in order to avoid potential post-treatment
stenosis. All of the bronchial tumors were roent-
genographically occult as evaluated by chest X-ray
and in most of them by computerized tomography.
Procedure
One hundred and twenty-one PDT treatments were
performed because 16 tumors were treated two or
three times. First generation photosensitizers (HPD
and Photofrin II) were used in 59 cases andmTHPC
in 62, respectively.
The HPD was provided freeze-dried by Hoff-
mann-La Roche and Ciba-Geigy (Basel, Switzer-
land) and Photofrin II was kindly supplied by
Quadra Logic Technology Inc. (Vancouver, BC,
Canada) as a lyophilized powder. Both compounds
were stored in the dark at 4C. Shortly before use,
they were dissolved in a sterile 5% glucose solution
and injected intravenously over a period of 10 min
at doses of 3 mg/kg for HPD and or 2 mg/kg for
Photofrin II. Irradiation was performed under gen-
eral anaesthesia 48 or 72 h after the administration
of the photosensitizer. Fifty-two of 59 PDTs with
HPD and Photofrin II were performed at 630nm
with an argon ion pumped dye laser (Spectra-
Physics). The remaining seven PDTs were com-
pleted at 514nm with the same argon ion laser
operated in the single-linemode. In theUAT and the
bronchi, all of the tumors were treated by surface
radiation using microlens and/or cylindrical light
distributors [22]. At the beginning of our study, we
used circumferential cylindrical light distributors
in the esophagus. Over the past eight years, due to
post-therapeutic esophageal stenosis, we have only
used 180 or 240 windowed cylindrical light dis-
tributors with a length of4 or 6cm [23,24]. The total
light doses ranged from 100 to 180 J/cm
2 at both
wavelengths. Light was delivered at an intensity
varying from 80 to 150mW/cm
2 with an exposure
time of about 20 min.
The mTHPC, provided by Scotia Pharmaceuti-
cals Ltd. (Guildford, UK), was dissolved in a
solution of 30% polyethylene glycol 400, 20%
ethanol, and 50% water. Less than half an hour
after its preparation, mTHPC was injected intrave-
nously over a period of 5-10min through a bac-
terial filter at doses of 0.3 mg/kg of body weight
(twice), 0.15 mg/kg (58 times) or 0.075 mg/kg
(twice). Photodynamic therapy was performed
under general anaesthesia 20 h (8 cases) and 96 h
(54 cases) after the injection ofthe dye. All but three
bronchial and UAT, but only three esophageal
irradiations were performed at 652 nm. The remain-
ing cases were treated with green light at 514 nm.
Lasers and light distributors were exactly the same
as those described above for PDT with HPD and
Photofrin II. Most ofthe 514nm illuminations were
carried out with total light doses of 75-120 J/cm
2
and an intensity of 100mW/cm2; whereas, the
majority of the 652nm irradiations were performed
with light doses of 8-12J/cm
2 and an intensity of
150mW/cm.2
In all cases, the size of the illumination area was
larger than the extent of the tumour. The reason for
the broad range oflight doses applied is that in some
cases, the light dose was adapted according to the
photosensitizer fluorescence signal measured onto
the tumour just before irradiation [25].
Follow-up
Patients were cautioned to avoid direct sunlight
exposure for 4-6 weeks after HPD or Photofrin II
administration and for 2 weeks after mTHPC
injection. Careful progressive exposure afterwards
was recommended during the next 2 months for
HPD and Photofrin II and the next 2-4 weeks for
mTHPC, respectively. A first endoscopic follow-up
was performed 7 or 10 days after PDT to assess148 A. RADU et al.
the extent of the tumour necrosis macroscopically.
Subsequent panendoscopies, done on an outpatient
basis with UAT and esophageal staining (Toluidine
blue), as well as biopsies and abrasive or wash cyto-
logies, were performed 3 months after the treat-
ment and subsequently twice a year thereafter.
Complete response to PDT was defined by the
absence of macroscopic signs of tumour at the
endoscopic examination and by negative biopsies,
cytological washings or brushings. Less than com-
plete response was characterized by the presence
of residual tumour on endoscopy or evidence of
malignancy on biopsies. Recurrence was considered
when a macroscopic or microscopic relapse of the
tumour occurred after an apparently complete
response at the third month endoscopic control.
RESULTS
One hundred and one SCCs of the UAT, the
esophagus, and the tracheobronchial tree were
treated by PDT with HPD, Photofrin II, and
mTHPC. Sixteen tumors were located in the oral
cavity and the pharynx, 49 in the esophagus, and
36 in the tracheobronchial tree. Maximal tumour
extension estimated at endoscopy ranged from to
3 cm in theUAT and from 0.3 to 4cm in the bronchi.
In the esophagus, the superficial longitudinal spread
of the turnout varied from to 6cm with radial
extensions between 60 and 200
Endoscopic controls 7 or 10 days after PDT
revealed not only necrosis of the tumour, but also
injuries in the surrounding normal irradiated
mucosa. True selectivity was never observed with
either photosensitizer administered and the extent
of the superficial tissue damage simply matched the
geometry of the illuminated area. All of the three
dyes showed important inter-individual variations
in terms oftumour damage, even in patients treated
with the same drug and light parameters. Although
difficult to quantify, variations seemed to be more
frequently noticed with mTHPC than with HPD or
Photofrin II.
Eighty-six (85%) early cancers had a complete
response (CR) with follow-up periods of 3 to 99
months (mean 27 months; median 25 months). Nine
of these 86 tumors recurred within an interval that
ranged from 3 to 34 months. The remaining 15
tumors showed less than CR, with all of them
presenting at least partial macroscopic reduction
in tumour size. Thus, PDT effectively eradicated 77
(76%) of the cancers evaluated. Examples of early
esophageal and bronchial SCC before and after
PDT are presented in Figs. and 2, respectively.
There was no important difference in CR rates
between the three treated sites. Twelve out of 16
(75%) tumors were cured in the UAT, 37 out of 49
(75.5%) in the esophagus, and 28 out of 36 (78%)
in the bronchi. The results showed similar PDT
efficacy whatever photosensitizer was used. Follow-
ing treatment with HPD and Photofrin II, 39 of 50
(75%) early cancers achieved a complete response,
whereas with mTHPC 38 of 51 (78%) tumors
were eradicated. However, as one could expect, the
tumour stage is of paramount importance in the
efficacy of the treatment even among early cancers.
In our study, in situ carcinomas had an 89% CR
rate, but the ratio fell to 66% in cases of micro-
invasive cancers. This lower rate ofsuccess is related
at least partially to understaging, as documented in
esophagectomy specimens, which showed tumoral
infiltration of the submucosa in some cases. The
results obtained by PDT with the different photo-
sensitizers as a function of the tumour staging and
treated site are presented in Tables I and II.
There was no procedure-related mortality. In all
cases, intravenous administration of the photo-
sensitizer was well tolerated, despite a slight
transient burning sensation localized around the
area of injection. There were no episodes of airway
compromise after PDT in the bronchi. Following
esophageal treatment, some patients reported mild
pain on swallowing that was well controlled by
short regimens oforal analgesics. The complications
of the treatment are listed in Table III. Esophago-
tracheal fistulas, which required surgery, occurred
in three patients within 3 weeks after red light
illumination of lesions located on the anterior wallPDT FOR EARLY CANCERS 149
(a) (b)
(c) (d)
FIGURE Micro-invasive (Tla) squamous cell carcinoma of the esophagus irradiated with green light (514nm) 4 days
after injection of 0.15 mg/kg of tetra(m-hydroxyphenyl) chlorin with a light dose of 160 J/cm and an intensity of 100mW/cm2.
(a) Endoscopic view of the tumour before treatment. (b) The same untreated lesion after toluidine blue staining; the extent of the
tumour is clearly outlined. (c) Seven days after treatment using a 240 windowed cylindrical light distributor; the radial necrosis
corresponds exactly to the irradiated area. (d) Complete response 3 months after photodynamic therapy.
of the mid-esophagus. Two other patients treated
with red light for an early tumour in the lower
esophagus developed a high-grade fever and pleural
effusion, respectively. Both complications were
considered as likely transmural necrosis with occult
perforation of the esophagus and resolved under
antibiotic treatment. Two esophageal stenoses were
induced after circumferential (360 irradiation and
were successfully managed by repeated bougienage
with a Savary-Gilliard dilator. Twelve patients
treated with mTHPC and one with HPD developed
skin photosensitization after disregarding the pre-
scribed precautions against sun exposure. All of
the mTHPC skin photosensitivity reactions were150 A. RADU e al.
(a) (b)
FIGURE 2 In situ squamous cell carcinoma of the bronchi treated with red light (652nm) 4 days after injection of 0.15mg/kg
of tetra(m-hydroxyphenyl) chlorin with a light dose of 12J/cm delivered at 150mW/cm2. (a) Pre-therapy endoscopic view.
(b) No residual tumour is seen on the bronchial spur 3 months after photodynamic therapy.
TABLE Results of photodynamic therapy with HPD and
Photofrin II for 51 early squamous cell carcinomas (SCC) in
the upper aerodigestive tract (UAT), the esophagus, and the
bronchi: Complete responses with no recurrence as a function
of the tumour staging and site
Location In situ SCC Micro-invasive SCC Total
UAT 3/3 4/7 7/10
Esophagus 7/8 9/13 16/21
Bronchi 7/8 8/12 15/20
Total 17/19 21/32 38/51
TABLE II Results of photodynamic therapy with mTHPC
for 50 early squamous cell carcinomas (SCC) in the upper
aerodigestive tract (UAT), the esophagus, and the bronchi:
Complete responses with no recurrence as a function of the
tumour staging and site
Location In situ SCC Micro-invasive SCC Total
UAT 3/4 2/2 5/6
Esophagus 9/10 12/18 21/28
Bronchi 11/12 2/4 13/16
Total 23/26 16/24 39/50
TABLE III Complications following photodynamic therapy
with HPD, Photofrin II, and mTHPC for 101 early cancers of
the UAT, the esophagus, and the bronchi
Esophagotracheal fistula 3




treatment. In all but one case, the skin reaction
was moderate and included redness, oedema, and
occasionally cutaneous blistering of the hands and
face. One patient experienced second degree burns
of the face, hand, and forearms after several hours
of exposure to sunlight two days after the photo-
sensitizer administration. The patient consequently
developed scars after healing.
DISCUSSION
observed within the first week after injection in
patients who did not follow the recommendations
for sun protection. The only skin reaction follow-
ingHPD administration occurred two months after
Photodynamic therapy is an emerging technique for
the treatment of various cancers, including those of
the head and neck, the esophagus, and the bronchi.
Its benefits are well known and undeniable.PDT FOR EARLY CANCERS 151
Photodynamic therapy is minimally invasive, non-
mutilating and causes few side effects. All of these
factors contribute to minimize mortality and mor-
bidity in patients who are already in poor general
condition. Since no resistance and no cumulative
toxicity have been yet observed, PDT can be
repeated multiple times. Photodynamic therapy
has also the potential to be used as a neo-adjuvant
treatment, as it involves a different curative process.
Another somewhat controversial advantage ofPDT
is the relative selectivity of the photosensitizer for
the pathological cells. This property, which allows a
selective necrosis ofthe tumour with preservation of
normal tissue, renders PDT more attractive than
other thermal techniques, such as laser or electro-
cautery. This benefit is ofparamount importance in
head and neck oncology, where standard treatments
generate a massive loss of tissue with eventual
functional sequelae.
In the head and neck field, the esophagus, and the
bronchi, PDT has been applied in both superficial
and invasive malignancies [26-31]. However, the
use of PDT to palliate advanced lesions has
shown only moderate advantages compared to
other methods such as thermal YAG laser vapor-
ization or endoprothesis [32,33]. Although PDT
temporarily reduces the volume of invasive tumors,
its benefit is limited by the severe complications,
such as haemorrhage and perforation, related to
the procedure [30,34]. Thus, the main interest in
using PDT is the cure of superficial cancers. This
technique has been successfully employed for
early malignancies in the oral cavity, the pharynx,
the gastrointestinal tract and the tracheobronchial
tree [35-41].
The results of our study confirm that PDT is an
efficient treatment for in situ and micro-invasive
squamous cell carcinomas of the UAT, the esopha-
gus, and the tracheobronchial tree. We have treated
more than 100 early tumors and have achieved a
complete response in 76% of them, with a mean
disease-free follow-up of 27 months. In most cases,
a single treatment was sufficient to eradicate the
lesion. The relatively low number of early cancers
treated in the oral cavity and the pharynx can be
explained by the fact that in these particular
locations, PDT does not seem to confer relevant
advantages in comparison to surgical excision with
a CO2 laser [42]. The CR rate after PDT is similar
in all three treated sites: UAT, esophagus, and
bronchi. This result tends to confirm that efficacy
ofPDT depends more on an accurate staging of the
tumour than on the location ofthe malignant tissue.
The importance of tumour staging in achieving a
CR is emphasized by the significantly lower rates
obtained in micro-invasive tumors (66%) compared
to in situ carcinomas (89%).
In all three sites, PDT withmTHPC shows results
similar to those obtained with first generation
photosensitizers (HPD and Photofrin II). However,
mTHPC displays several clinical advantages. Its
phototoxicity is much higher as compared to HPD
and Photofrin II [18], which implies that lower
light doses and shorter illumination times can be
used without impairing the treatment efficacy. Brief
irradiation times as low as, for example one minute
in the bronchi with red light, avoid variations in
dosimetry by limiting the movements of light
distributors. Skin photosensitivity, as previously
reported, is shorter with mTHPC than with HPD
or Photofrin II [43]. In our study, all of the
cutaneous reactions following treatment with
mTHPC always occurred within the first week after
injection; whereas, a second degree sunburn hap-
pened 2 months after HPD administration. In
addition, the higher fluorescence quantum yield
displayed by mTHPC enables the important inter-
individual variations of tumour fluorescence to be
measured just before illumination and thus the light
dose delivered to the lesion can be adjusted [25].
Several factors could explain the 24% rate of
treatment failures. Undoubtedly, tumour under-
staging is one ofthem. In five cases, esophagectomy
was performed, as PDT failed to cure the tumors.
Histopathological analysis ofthe surgical specimens
showed submucosal carcinomas (T1b stage) in four
cases and limited tumoral invasion ofthe muscularis
propria in the fifth. These cases stress the difficult
problem of an accurate differentiation between
intramucosal (Tla) and submucosal (Tlb)152 A. RADU et al.
carcinomas. Since staging of superficial tumors
based on morphological criteria is highly dependent
on the endoscopist’s experience, more complex
imaging systems should be developed in the near
future. Another possible reason for the less than
complete response noticed in some treatments is
that tumors are likely to be only partially included in
the illumination field. The complex geometry of
some lesions, such as bronchial tumors expanding
from a spur into different adjacent segmental
divisions, probably plays a role in the non-steriliza-
tion of the tumors. Esophageal folds likely caused
the irregular tumour necrosis thatwas noticed at the
first follow-up endoscopic examination in some
cases. In one patient, the frequent sliding of the
esophagus due to a hiatal hernia presumably
prevented homogenous light delivery. Finally,
interpatient variability in the dye concentration at
the time of PDT might be responsible for the
incomplete eradication of some lesions. Following
administration of identical drug and light param-
eters to different patients, we noticed awide range of
light-induced fluorescence signals in the tissues
measured just before PDT, which correlated well
with the consequent insufficient or massive degree
of tumour necrosis. Therefore, adjusting the light
dose to the dye fluorescence signal prior to irradia-
tion could help to minimize the risk ofundertreating
the lesions.
In our study, all but one major complication
occurred following red light illumination. Esopha-
geal perforation with esophagotracheal or esopha-
gomediastinal fistula formation after PDT for
invasive cancers has been previously reported
[30,44]. These complications are most often related
to the extensive necrosis generated by the treatment.
However, in the case of early carcinomas, trans-
mural necrosis after PDT is the result of the lack of
true selectivity of the photosensitizer’s distribution
between the tumour and the underlying healthy
tissue [11,45-47]. Thus, as the red light penetrates
deeply into the tissues, illumination at 630 or 652nm
in the esophagus may not only cause destruction
of the early cancer but also of the smooth muscle
layers underneath with subsequent perforation of
the esophageal wall. Irradiation with green light,
which acts more superficially [48], tends to compen-
sate the poor selectivity of the dyes. Since 1992,
when we started illuminating early esophageal
cancers with 514nm light, we have not experienced
these complications. Furthermore, the use of green
light did not adversely affect the efficacy of
PDT [49]. In the superficial bronchial cancers as
defined here, where by definition the cartilage is
not invaded, a transmural necrosis with perfor-
ation and fistula formation following PDT is very
unlikely to occur. As the bronchial cartilage accu-
mulates only minimal amounts of photosensitizers
[50], red light illumination can be safely used. The
insufficient therapeutic selectivity of the dyes is
underlined by the occurrence in our study of two
esophageal stenoses. Even though the tumour to
be treated was not circular, a 360 illumination
induced a circumferential necrosis that caused a
subsequent stricture. Therefore, the application of
180 or 240 windowed light distributors in our
study has limited the extent of tissue damage and
has prevented the development of further esopha-
geal stenoses.
Our study confirms that PDT is an effective
modality for the treatment of early cancer in the
UAT, the bronchi, and the esophagus. In addition,
the use of optimal light dosimetry with adequate
light diffusers renders PDT safer. However, devel-
opment of new photosensitizers with increased
selectivity and limited skin photosensitization, as
well as improvement of the light delivery systems
should contribute to the expansion and worldwide
acceptance of this treatment.
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